Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis

References

• Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone re-sorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943–51.
   PubMed Web of Science ®Google Scholar
• Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619–33.
   PubMed Web of Science ®Google Scholar
• Krane SM. Mechanism of tissue destruction in rheumatoid arthri-tis. Arthritis and allied conditions. 12th ed. Malvern, PA: Lea & Febiger; 1993.
   Google Scholar
• Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoar-ticular and pauciarticular juvenile rheumatoid arthritis. J Bone Joint Surg (A) 1981;63(2):209–15.
   Google Scholar
• Meade EA, Smith WL, DeWitt DL. Differential inhibition of pros-taglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268(9):6610–4.
   Google Scholar
• O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994;45(2):245–54.
   PubMedGoogle Scholar
• Bombardieri S, Cattani P, Ciabattoni G, Di Munno 0, Pasero G, Patrono C, et al. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and non-steroidal anti-inflammatory drugs. Br J Pharmacol 1981;73(4): 893–901.
   Google Scholar
• Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflam-mation. Annu Rev Immunol 1984;2:335–57.
   Google Scholar
• O'Neill GP, Ford-Hutchinson AW. Expression of mFtNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330(2):156–60.
   PubMed Web of Science ®Google Scholar
• Crofford LL COX-2 in synovial tissues. Osteoarthritis Cartilage 1999;7(4):406–8.
   PubMedGoogle Scholar
• Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, et al. Prostaglandin G/H synthase-2 is required for maxi-mal formation of osteoclast-like cells in culture. J Chin Invest 2000;105(6):823–32.
   PubMed Web of Science ®Google Scholar
• Okada Y, Pilbeam C, Raisz L, Tanaka Y. Role of cyclooxygenase-2 in bone resorption. J UOEH 2003;25(2):185–95.
   PubMedGoogle Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identi-cal to TFtANCE/FtANKL. Proc Natl Acad Sci USA 1998;95(7): 3597–602.
   PubMed Web of Science ®Google Scholar
• Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002;109(1):109–15.
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Chikazu D, Nakamura K, Kumegawa M, Hakeda Y. Direct and indirect actions of fibroblast growth factor 2 on os-teodastic bone resorption in cultures. J Bone Miner Res 2000;15(3): 466–73.
   Google Scholar
• Igarashi K, Woo JT, Stern PH. Effects of a selective cyclooxygen-ase-2 inhibitor, celecoxib, on bone resorption and osteoclastogen-esis in vitro. Biochem Pharmacol 2002;63(3):523–32.
   Google Scholar
• Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, et al. Suppression of adjuvant-induced arthritic bone destruc-tion by cyclooxygenase-2 selective agents with and without inhibi-tory potency against carbonic anhydrase II. J Bone Miner Res 2006;21(2):219–27.
   PubMedGoogle Scholar
• Mastbergen SC, Lafeber FP, Bijlsma JW. Selective COX-2 inhibi-tion prevents proinflammatory cytokine-induced cartilage damage. Ftheumatology (Oxford) 2002;41(7):801–8.
   Google Scholar
• Bogoch E, Gschwend N, Bogoch B, Rahn B, Perren S. Juxta-articular bone loss in experimental inflammatory arthritis. J Orthop Res 1988;6(5):648–56.
   Google Scholar
• Takahi K, Hashimoto J, Hayashida K, Shi K, Takano H, Tsuboi H, et al. Early closure of growth plate causes poor growth of long bones in collagen-induced arthritis rats. J Musculoskelet Neuronal Interact 2002;2(4):344–51.
   PubMedGoogle Scholar
• Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, et al. Suppressed severity of collagen-induced ar- thritis by in vivo transfection of nuclear factor IcB decoy oligode-oxynucleotides as a gene therapy. Arthritis Rheum 1999;42(12): 2532–42.
   PubMed Web of Science ®Google Scholar
• Nagy TR, Prince CW, Li J. Validation of peripheral dual-energy X-ray absorptiometry for the measurement of bone mineral in in-tact and excised long bones of rats. J Bone Miner Res 2001;16(9): 1682–7.
   Google Scholar
• Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, et al. Increased bone formation by intermittent par-athyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994;15(6):717–23.
   PubMed Web of Science ®Google Scholar
• Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, MaRuche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histo-morphometry Nomenclature Committee. J Bone Miner Res 1987; 2(6):595–610.
   PubMed Web of Science ®Google Scholar
• Hanyu T, Chotanaphuti T, Arai K, Tanaka T, Takahashi HE. Histomorphometric assessment of bone changes in rats with type II collagen-induced arthritis. Bone 1999;24(5):485–90.
   Google Scholar
• Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteo-clast differentiation factor. Arthritis Rheum 2000;43(2):250–8.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, lizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclas-togenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43(2):259–69.
   PubMed Web of Science ®Google Scholar
• Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid ar-thritis. Arthritis Rheum 2000;43(142523–30.
   Google Scholar
• Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheu-matoid arthritis. Ftheumatology (Oxford) 2002;41(141232–39.
   Google Scholar
• Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthri-tis. Arthritis Res 2002;4(5):281–9.
   Google Scholar
• Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independ-ently of Bc1-2. J Biol Chem 2000;275(15):11397–403.
   PubMed Web of Science ®Google Scholar
• Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15(14):2742–4.
   Google Scholar
• Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masfer-rer JL. Cyclooxygenase-2 inhibition by celecoxib reduces prolifera-tion and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62(3):625–31.
   Google Scholar
• Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other se-lective cyclooxygenase 2 inhibitors. Arthritis Rheum 2002;46(12): 3159–67.
   Google Scholar
• Kusunoki N, Ito T, Sakurai N, Suguro T, Handa H, Kawai S. A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. J Pharmacol Exp Ther 2005;314(2):796–803.
   PubMed Web of Science ®Google Scholar
• Kawai S, Nagai K, Nishida S, Sakyo K, Mural E, Mizushima Y. Low-dose pulse methotrexate inhibits articular destruction of ad-juvant arthritis in rats. J Pharm Pharmacol 1997;49(2):213–5.
   PubMedGoogle Scholar
• Segawa Y, Yamaura M, Aota S, Omata T, Tuzuike N, Itokazu Y, et al. Methotrexate maintains bone mass by preventing both a de-crease in bone formation and an increase in bone resorption in adjuvant-induced arthritic rats. Bone 1997;20(5):457–64.
   PubMedGoogle Scholar
• Takagi T, Tsao PW, Totsuka R, Suzuki T, Murata T, Takata I. Dexamethasone prevents the decrease of bone mineral density in type II collagen-induced rat arthritis model. Jpn J Pharmacol 1998;78(2):225–8.
   PubMedGoogle Scholar
• Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vas-cular endothelial growth factor expression in colon cancer cells by enhanced degradation of Spl and Sp4 proteins. Mol Pharmacol 2005;68(2):317–29.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Mateus MM, Defresne MP, Crielaard JM, Reginster JY, Henrotin YE. R Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin lbeta and nonsteroidal anti-inflammatory drugs. J Ftheumatol 2002;29(4): 772–82.
   Google Scholar
• Chrysis D, Ftitzen EM, Savendahl L. Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 2003;176(3):331–7.
   Google Scholar
• McDonagh JE. Osteoporosis in juvenile idiopathic arthritis (Review). Curr Opin Ftheumatol 2001;13(5):399–404.
   PubMedGoogle Scholar